// App-Quantinova.ai

: GENOTYPE-GUIDED P2Y12 INHIBITION FOLLOWING PCI BENEFITS CYP2C19 LOSS OF FUNCTION PATIENTS WITH NORMAL RENAL FUNCTION COMPARED TO THOSE WITH CHRONIC KIDNEY DISEASE

Researchers

Presenter

  • Roy Mathew

Principal Investigators

  • Mandeep Sidhu

  • Michael Farkouh

  • Charanjit Rihal

  • Ryan Lennon

  • Mohammad El-Hajjar

  • Neil Yager

  • Khaled Abdul-Nour

  • Steven Weitz

  • Deaglan O'Cochlain

  • Justin Levisay

  • Vishubhakta Murthy

  • John Graham

  • Vladimir Dzavik

  • Kevin Marzo

  • Derek So

  • Shaun Goodman

  • Naveen Pereira

Medical Centers

  • Montreal Heart Institute, Universite Montreal, Montreal, QC, Canada

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

  • Central Nervous System (CNS)

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic kidney disease

  • Myocardial infarction

  • Renal disease

  • Venous thrombosis

  • Coronary Artery Disease

  • Stroke

Biomarkers

  • Cytochrome P450 2C19

Drug/Treatment

  • Clopidogrel bisulfate

  • Ticagrelor

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved